Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient's Perspectives

Samantha Pasca

doi:10.2147/JBM.S242219

Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient's Perspectives

J Blood Med. 2022 Apr 16:13:191-199. doi: 10.2147/JBM.S242219. eCollection 2022.

Author

Samantha Pasca^{1

2}

Affiliations

¹ Medicine Department (DIMED) - Padua University Hospital, Padua, Italy.
² Biomedical Sciences Department (DSB) - Padua University Hospital, Padua, Italy.

Abstract

Concizumab is a monoclonal, humanized IgG4 antibody specific for the Kunitz-2 domain of Tissue Factor Pathway Inhibitor (TFPI). Preclinical studies in vitro or on animal models and in vivo have demonstrated the ability of concizumab to restore thrombin generation, promoting the establishment of a procoagulant action; all these results were subsequently confirmed in the studies of EXPLORER program. Concizumab may represent a new opportunity for the treatment of persons with hemophilia, so there is much anticipation for the results of the ongoing trials still. This review retraces all the studies on concizumab published to date, with a brief discussion about the patient' perspectives.

Keywords: anti-TFPI antibodies; concizumab; hemophilia; new hemophilia treatments.

Publication types

Review